The global leptospirosis market is estimated to be valued at US$ 496.8 million in 2023 and is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030).
Analysts’ Views on Global Leptospirosis Market:
Global leptospirosis market's growth is expected to drive the growth of the market owing to the increasing disease awareness by government authorities for the treatment of leptospirosis. For instance, on November 28, 2022, the government of the Republic of Trinidad and Tobago, Port of Spain, announced a statement regarding leptospirosis awareness for the public to protect against leptospirosis, which shows symptoms like high fever, headache, muscle aches, diarrhoea, jaundice, and other symptoms. As a result, government officials advised the public to get tested for leptospirosis before beginning early treatment.This is expected to increase the demand for medicines in the region for the treatment of leptospirosis in the near future.
Figure 1. Global Leptospirosis Market Share (%), By Drug, 2023
To learn more about this report, Request sample copy
Global Leptospirosis Market – Driver
Ongoing research and development by key market players
Ongoing research and development for vaccine development against leptospirosis by key market players are expected to drive the global leptospirosis market over the forecast period. For instance, on January 26, 2021, eLife, a non-profit organization created by funders and led by researchers, issued a statement stating that the scientists had designed a single-dose universal vaccine that could protect against the many forms of leptospirosis bacteria. According to a study published in eLife, a peer-reviewed journal, an effective vaccine would help prevent the life-threatening conditions caused by leptospirosis, such as Weil’s disease and lung hemorrhage, which are fatal in 10% and 50% of cases, respectively. In the preclinical study, the data has shown that a universal leptospirosis vaccine candidate can prevent both death and kidney colonization in animal models.
Figure 2. Global Leptospirosis Market Value (US$ Million), by Region, 2023
To learn more about this report, Request sample copy
Global Leptospirosis Market- Regional Analysis
Among regions, Africa is estimated to hold a dominant position in the global leptospirosis market over the forecast period owing to the increasing prevalence of leptospirosis in the region. For instance, on July 14, 2022, according to the World Health Organization (WHO), the Ministry of Health (MoH) of the United Republic of Tanzania, Africa, notified WHO of 13 cases of leptospirosis. The first two cases were presented to a health center located in Ruangwa District, Lindi Region, on July 5 and 7,2022, with symptoms of fever, bleeding from the nose, headache, and general body weakness. Thus, the demand for the drug required for leptospirosis treatment is going to rise in the near future, which is expected to drive the growth of the market over the forecast period.
Global Leptospirosis Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a negative impact on the global leptospirosis market. For instance, on January 10, 2022, an article published in the Korean Society of Epidemiology, a scientific journal, stated about the outbreak of leptospirosis in Sri Lanka during the COVID-19 pandemic that the coronavirus disease 2019 (COVID-19) pandemic disrupted the global health systems and affected the transmission dynamics as well as the surveillance of other infectious diseases. This study described the probable effect of the COVID-19 pandemic on the surveillance and control of leptospirosis in Sri Lanka. With 8,579 reported cases and more than 800 estimated deaths, the Sri Lankan public health surveillance system documented the largest outbreak of leptospirosis in Sri Lankan history in 2020. This was the worst infectious disease outbreak Sri Lanka experienced in 2020, but it was neglected, primarily due to the COVID-19 pandemic.
Leptospirosis Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 496.8 Mn |
Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 to 2030 |
Forecast Period 2023 to 2030 CAGR: | 5.8% | 2030 Value Projection: | US$ 739.6 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
USAntibiotics, Dr. Reddy’s Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical Industries, Inc., Ralington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd., and Aden Healthcare |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Leptospirosis Market Segmentation:
The global leptospirosis market report is segmented into Drug, Diagnosis, Route of Administration, and Distribution Channel
Based on Drug, the market is segmented into amoxicillin, azithromycin, cefixime, doxycycline, and others (ceftriaxone, penicillin among others). Out of which, the amoxicillin segment is expected to dominant position in global leptospirosis market during the forecast period and this is attributed due to the increase in the use of Amoxicillin for the treatment of Leptospirosis based on guidelines published by government authorities.
Based on Diagnosis, the market is segmented into complete blood count (CBC), creatine kinase, liver enzymes, urinalysis, and others which include lumbar puncture, microscopic agglutination test, and others. Out of which, completed blood count (CBC) segment is expected to dominate the market over the forecast period.
Based on Route of Administration, the market is segmented into oral, parenteral, and intravenous. Out of which, oral segment is expected to dominate the market over the forecast period and this is attributed to the increased use of antibiotics for the treatment of leptospirosis.
Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to the increase in the number of hospital pharmacies.
Based on Region, Africa is expected to hold a dominant position in the market among all the regions due to increasing awareness programs in the regions for leptospirosis for early detection and treatment
Among all segmentation, drug segment has the highest potential due to the increasing use of off-label antibiotics for the treatment of leptospirosis as there is no approved product by regulatory authorities available in the market.
Global Leptospirosis Market Cross Sectional Analysis:
In the distribution channel segment, hospital pharmacies held a dominant segment in North America region due to the increasing number of hospital pharmacies. For instance, in January 2022, according to data provided by the National Association of Pharmacy Regulatory Authorities, there were 11,814 pharmacies in Canada in January 2022.
Global Leptospirosis Market: Key Developments
Increasing expansion of diagnostics laboratory for leptospirosis by government authorities over the forecast period. For instance, On November 11, 2022, The Minister for Health and Family Welfare of Tamil Nadu, India, announced the inauguration of the Regional Leptospirosis Diagnostics Laboratory (RLDL) to strengthen diagnostic facilities for leptospirosis at the State Public Health Laboratory of the Directorate of Public Health (DPH) and Preventive Medicine in Chennai, India.
Global Leptospirosis Market: Key Trends
Increasing adoption of highly efficient diagnostic methods for the detection of leptospirosis
Increasing adoption of highly efficient diagnostic methods for the detection of leptospirosis is expected to drive the global leptospirosis market over the forecast period. For instance, on September 30, 2022, an article published by Research Square, a peer-reviewed journal, stated that "Early diagnosis by metagenomics next-generation sequencing (mNGS) improves the prognosis for severe leptospirosis patients," which resulted in "mNGS being highly efficient in diagnosing leptospirosis and could reduce the mortality rate if used at an early stage." This was expected to raise the demand for treatment after early detection, which is expected to drive the growth of the market over the forecast period.
Global Leptospirosis Market: Restraint
Lack of standardization of diagnostic testing and treatment alternatives for the prevention and control of Leptospirosis
Global leptospirosis market growth can be hindered by lack of standardization of diagnostic testing and approved treatment alternatives for the prevention and control of leptospirosis. For instance, on September 22, 2021, According to the data published by the Department Of Health And Mental Hygiene Human cases of leptospirosis, New York City. the staeted that Fourteen people diagnosed with leptospirosis have been reported to date in 2021, more than the total number reported to the New York City Health Department in any prior year. The majority of patients were hospitalized with acute renal and hepatic failure, two of whom also had severe pulmonary involvement. Leptospirosis is treated with antibiotics, such as doxycycline or penicillin, which should be given early in the course of the disease.
Thus it is required to focus on research and development activities for the development of drugs indicated for the treatment of Leptospirosis
Global Leptospirosis Market - Key Players
Major players operating in the global leptospirosis market include USAntibiotics, Dr. Reddy’s Laboratories Ltd., Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical Industries, Inc., Ralington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd., and Aden Healthcare
*Definition: Leptospirosis is a bacterial disease that affects humans and animals. It is caused by bacteria of the genus Leptospira. In humans, it can cause a wide range of symptoms, some of which may be mistaken for other diseases. Some infected persons, however, may have no symptoms at all.
Global Leptospirosis Market– Insights
The bacterial illness leptospirosis can affect both people and animals. Leptospira bacteria are to blame for their development. It can have a wide range of symptoms in people, some of which may be confused with those of other illnesses. However, some infected people might not even exhibit any symptoms. Leptospirosis is contracted by water or by diseased animals' urine, which contains germs that can persist for weeks or months in soil. The bacterium is carried by many different species of wild and domesticated animals.
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients